Sequential Announces New Collaboration Agreement to Quantify Skin Health

15 Mar 2023
www.biospace.com
Microbial therapyClinical Study
NEW YORK, March 15, 2023 /PRNewswire/ -- Sequential Skin Inc. ("Sequential"), the skin microbiome company developing next generation non-invasive skin testing and data-driven solutions for the skin microbiome, today announced that it has entered into a collaboration agreement with Johnson & Johnson Consumer Inc. "This collaboration will give us the opportunity to improve upon our novel technologies at Sequential, to further understand how molecular changes on the skin may translate to skin and human health," said Oliver Worsley, CEO and Co-Founder of Sequential Skin. The collaboration will focus on developing new methods for non-invasive genomic-based skin testing, to help Sequential add to their growing database of skin samples. To learn more about Sequential's work as the leading microbiome testing partner, visit . About Sequential Sequential is the industry leader in microbiome testing, claims substantiation and support for brands formulating products for skin, scalp, intimate care and oral care. Recognized as the most significant testing solution in the industry, Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. Sequential's testing is exclusively managed in-house and with human clinical subjects, in vivo. As an ally in research and development to top global brands and household names, Sequential supports their journey to delivering consumer driven products backed in science. To learn more visit . For More Information: Lexington Public Relations suki@lexingotnpr.com Dr Oliver Worsley | CEO and Co-Founder Dr Albert Dashi | CSO and Co-Founder investors@sequential.bio Logo - Photo - View original content to download multimedia: SOURCE Sequential Skin
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.